Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.47 |
| ▸ | MMP8 | P22894 | 6/20 | 0.47 |
| ▸ | MMP9 | P14780 | 5/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.47 |
| ▸ | CCKBR | P32239 | 9/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.43 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | ECE1 | P42892 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26421722 | 0.88 | MMP2 (0.54) | MMP2MMP8MMP9MMP1CCKBR | |
| SCHEMBL26421800 | 0.85 | NPY1R (0.46) | MMP2MMP8MMP9CCKBR | |
| SCHEMBL26421849 | 0.80 | KISS1R (0.47) | MMP2MMP8MMP9CCKBR | |
| SCHEMBL26421774 | 0.78 | EDNRA (0.55) | MMP2MMP8MMP9MMP1CCKBR | |
| SCHEMBL24668049 | 0.77 | MMP2 (0.53) | MMP2MMP8MMP9MMP1CCKBR | |
| SCHEMBL30096974 | 0.77 | KDM4E (0.52) | MMP2MMP8MMP9MMP1ACE | |
| SCHEMBL29884162 | 0.77 | GHSR (0.54) | — | |
| SCHEMBL30450384 | 0.77 | GHSR (0.54) | — | |
| SCHEMBL30643024 | 0.76 | CTSL (0.65) | CCKBRCTSLCTSSCTSKACE | |
| SCHEMBL30059119 | 0.76 | GHSR (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | KLEO PHARMACEUTICALS, INC. | 2023-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230128688-A1 | DIRECTED CONJUGATION TECHNOLOGIES | CD2BP2, CD2, CD47 | MMP2 1511/4885MMP8 1244/4885MMP9 2922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.